Lumos Pharma

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for rare diseases. Its product includes LUM-201, an oral growth hormone stimulating small molecule for the treatment of pediatric growth hormone deficiency (PGHD). The company was founded on June 4, 1999 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Lumos Pharma excels in Q1 with FDA nod for LUM-201

Lumos Pharma's Q1 2024 earnings call showcased strong performance, financial stability, and promising updates on LUM-201, positioning the company for growth and success in the pharmaceutical industry.
While facing challenges in trial design, enrollment criteria, and funding, Lumos Pharma's innovative approach and positive market reception offer opportunities for market expansion and patient impact.
The call emphasized the potential advantages of LUM-201, the company's robust pipeline, and the importance of securing capital post-FDA trial design approval, setting the stage for future growth and development.

Lumos Pharma progresses LUM-201, seeks strategic partnerships for growth

Lumos Pharma's Q2 2024 performance reflects a strategic focus on advancing LUM-201 and managing costs.
Despite financial challenges and limited cash reserves, the company is leveraging opportunities for growth.
Engagement with Piper Sandler and positive trial data position Lumos Pharma for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AUSTIN, Texas, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Lumo s Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company will participate in the virtual H.C. Wainwright BioConnect 2021 Conference to be held January 11-14, 2021.

Lumos Pharma to Participate in the H.C. Wainwright BioConnect 2021 Conference

AUSTIN, Texas, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company will present and host one-on-one meetings at the following virtual investor conferences to be held in December:

Lumos Pharma to Participate in December Investor Conferences

Lumos Pharma, Inc. (LUMO) CEO Rick Hawkins on Q3 2020 Results - Earnings Call Transcript

AUSTIN, Texas, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.  (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial results for the third quarter ended September 30, 2020 and provided an update on clinical activities.

Lumos Pharma Announces the Initiation of Phase 2b OraGrowtH210 Trial and Reports Third Quarter 2020 Financial Results

Lumos (LUMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Lumos Pharma (LUMO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

AUSTIN, Texas, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company will present and host one-on-one meetings at the following virtual investor conferences to be held in November:

Lumos Pharma to Participate in November Investor Conferences

AUSTIN, Texas, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its third quarter 2020 financial results after market close on Tuesday, November 10, 2020. The company will host a conference call and webcast at 4:30 PM ET that day to discuss its third quarter financial results and provide an update on corporate activities. There will also be a question and answer session following the prepared remarks.

Lumos Pharma to Report Third Quarter 2020 Financial Results and Host a Conference Call on November 10, 2020

Lumos Pharma, Inc. (LUMO) CEO Rick Hawkins on Q2 2020 Results - Earnings Call Transcript

AUSTIN, Texas, Aug.  13, 2020  (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial results for the second quarter ended June 30, 2020 and provided an update on clinical activities.

Lumos Pharma Reports Second Quarter 2020 Results and Provides Update on Clinical and Corporate Activities

AUSTIN, Texas, July  28, 2020  (GLOBE NEWSWIRE) --  Lumos Pharma, Inc.  (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its second quarter 2020 financial results after market close on Thursday, August 13, 2020. The company will host a conference call and webcast at 4:30 PM ET that day to discuss its second quarter financial results and provide an update on corporate activities. There will also be a question and answer session following the prepared remarks.

Lumos Pharma to Report Second Quarter 2020 Financial Results and Host a Conference Call on August 13, 2020

AUSTIN, Texas, July  27, 2020  (GLOBE NEWSWIRE) --  Lumos Pharma, Inc.  (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that it has entered into a definitive agreement to sell its Priority Review Voucher (PRV) to Merck, known as MSD outside the United States and Canada.

Lumos Pharma Announces Sale of Priority Review Voucher

As of late, it has definitely been a great time to be an investor in Lumos Pharma.

Lumos Pharma's Shares March Higher, Can It Continue?

News for Lumos Pharma Stock (LUMO)